Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

105.18 USD -0.82 (-0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 321,793
Open 104.19
Bid (Size) 80.05 (1)
Ask (Size) 200.60 (1)
Prev. Close 106.00
Today's Range 104.19 - 105.52
52wk Range 76.65 - 125.61
Shares Outstanding 58,574,031
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on September... 
From PR Newswire
Blueprint Medicines to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that Kate Haviland, Blueprint Medicines' Chief Operating Officer, and Fouad Namouni, M.D., Blueprint Medicines' President, Research &... 
From PR Newswire

Performance

YTD
+0.58%
+0.58%
1 Month
+9.41%
+9.41%
3 Month
+27.06%
+27.06%
6 Month
+0.18%
+0.18%
1 Year
+36.23%
+36.23%

More News

Read More
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
Blueprint Medicines Reports Second Quarter 2021 Financial Results
From PR Newswire
MD Anderson and Blueprint Medicines Announce Strategic Collaboration to Accelerate BLU-222 Development
From PR Newswire
Blueprint Medicines to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
From PR Newswire
Notable Thursday Option Activity: BPMC, FOSL, OSTK
Tags Stocks
From Market News Video
Blueprint Medicines: Q2 Earnings Insights
Tags Earnings Market News Benzinga
From Benzinga
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Tags AZN RHHBY BPMC
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.